BMS Lung Cancer Drug Fails Clinical Tests

12.10.2016 - The newly developed Bristol-Myers (BMS) lung cancer drug Opdivo, a so-called checkpoint inhibitor that stimulates the immune system so that it can attack malignant tumours, has...